Outcomes of Stage IIIA Endometrial Cancer with Adnexa or Serosal Involvement
Author Information
Author(s): Jobsen Jan J., Naudin ten Cate Lambert, Lybeert Marnix L. M., Scholten Astrid, van der Steen-Banasik Elzbieta M., van der Palen Job, Stenfert Kroese Marika C., Slot Annerie, Schutter Eltjo M. J., Siesling Sabine
Hypothesis
This study aims to look at possible differences in outcome between serosa and adnexal involvement in stage IIIA endometrial carcinoma.
Conclusion
Endometrial carcinoma stage IIIA with involvement of the adnexa or serosa showed comparable disease-specific survival, but locoregional control was worse for serosa involvement compared to adnexa.
Supporting Evidence
- The 7-year locoregional failure rate was 2.2% for adnexal involvement and 16.0% for serosal involvement.
- The 7-year distant metastasis-free survival was 72.7% for adnexal involvement and 58.7% for serosal involvement.
- The 7-year disease-specific survival was 71.8% for patients with adnexal involvement and 75.4% for patients with serosal involvement.
Takeaway
This study looked at women with a specific type of cancer and found that those with certain types of cancer spread had similar chances of surviving, but some had more problems with cancer coming back.
Methodology
The study included 67 patients with stage IIIA endometrial carcinoma, comparing outcomes based on whether they had adnexal or serosal involvement.
Potential Biases
Potential selection bias due to the multicenter nature of the study and differences in treatment protocols.
Limitations
The study is retrospective and spans a 15-year period, which may introduce selection bias and variability in treatment protocols across institutions.
Participant Demographics
Patients ranged in age from 40 to 87 years, with a median age of 67 years.
Statistical Information
Confidence Interval
95% CI 1.03–9.11
Statistical Significance
p=0.0522
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website